Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 121Lung Neoplasms 49Triple Negative Breast Neoplasms 35Breast Neoplasms 33Small Cell Lung Carcinoma 29Squamous Cell Carcinoma of Head and Neck 24Ovarian Neoplasms 24Neoplasm Metastasis 21Fallopian Tube Neoplasms 19Endometrial Neoplasms 19Parkinson Disease 4, Autosomal Dominant Lewy Body 15Neoplasms 15Head and Neck Neoplasms 12Colorectal Neoplasms 11Carcinoma 10Oropharyngeal Neoplasms 9Esophageal Neoplasms 9Urinary Bladder Neoplasms 8Prostatic Neoplasms 8Carcinoma, Transitional Cell 8Pancreatic Neoplasms 7Carcinoma, Squamous Cell 7Carcinoma, Ovarian Epithelial 6Adenocarcinoma of Lung 6Uterine Cervical Neoplasms 5Mouth Neoplasms 5Mesothelioma 5Lung Diseases 5Laryngeal Neoplasms 5Respiratory Tract Neoplasms 4

Interventions

Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroendocrine Neoplasms × Carboplatin × 90 days × Clear all
NCT06132113 2026-05-27

DAREONâ„¢-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Boehringer Ingelheim

Phase 1 Recruiting
55 enrolled
Endocrine

Neuroendocrine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡